Probiotics tested as infection shield for ICU patients

NCT ID NCT07164781

ENROLLING_BY_INVITATION Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether giving probiotics (Bacillus clausii) to critically ill adults can reduce serious infections like pneumonia and bloodstream infections. One hundred ICU patients will receive either the probiotic or a sugar pill, and researchers will track infection rates and length of hospital stay. The goal is to see if a simple, safe supplement can help protect vulnerable patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bacillus clausii (a type of probiotic)
What this could lead to: If it works, this could point toward a simple, low-cost way to lower infection rates in intensive care patients.
What could go wrong: This is a small, early-stage trial with only 100 patients. Probiotics may not prevent infections, and results may not apply to all ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATHETER-RELATED BLOODSTREAM INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diarrheal disease Pneumonia, Ventilator-Associated Toxemia urinary tract infection infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Benha University Hospitals

Banhā, Qalyubia Governorate, 13518, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.